156 related articles for article (PubMed ID: 22021368)
1. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors.
Nakagawa M; Shimabe M; Watanabe-Okochi N; Arai S; Yoshimi A; Shinohara A; Nishimoto N; Kataoka K; Sato T; Kumano K; Nannya Y; Ichikawa M; Imai Y; Kurokawa M
Blood; 2011 Dec; 118(25):6626-37. PubMed ID: 22021368
[TBL] [Abstract][Full Text] [Related]
2. Runt-Related Transcription Factor 1 Regulates LPS-Induced Acute Lung Injury via NF-κB Signaling.
Tang X; Sun L; Jin X; Chen Y; Zhu H; Liang Y; Wu Q; Han X; Liang J; Liu X; Liang Z; Wang G; Luo F
Am J Respir Cell Mol Biol; 2017 Aug; 57(2):174-183. PubMed ID: 28314106
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
4. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.
Vilimas T; Mascarenhas J; Palomero T; Mandal M; Buonamici S; Meng F; Thompson B; Spaulding C; Macaroun S; Alegre ML; Kee BL; Ferrando A; Miele L; Aifantis I
Nat Med; 2007 Jan; 13(1):70-7. PubMed ID: 17173050
[TBL] [Abstract][Full Text] [Related]
5. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
6. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF.
Nishimoto N; Arai S; Ichikawa M; Nakagawa M; Goyama S; Kumano K; Takahashi T; Kamikubo Y; Imai Y; Kurokawa M
Blood; 2011 Sep; 118(9):2541-50. PubMed ID: 21757616
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
8. A role for RUNX1 in hematopoiesis and myeloid leukemia.
Ichikawa M; Yoshimi A; Nakagawa M; Nishimoto N; Watanabe-Okochi N; Kurokawa M
Int J Hematol; 2013 Jun; 97(6):726-34. PubMed ID: 23613270
[TBL] [Abstract][Full Text] [Related]
9. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
11. Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression.
Gattenloehner S; Chuvpilo S; Langebrake C; Reinhardt D; Müller-Hermelink HK; Serfling E; Vincent A; Marx A
Blood; 2007 Sep; 110(6):2027-33. PubMed ID: 17431130
[TBL] [Abstract][Full Text] [Related]
12. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.
Wang L; Zhao WL; Yan JS; Liu P; Sun HP; Zhou GB; Weng ZY; Wu WL; Weng XQ; Sun XJ; Chen Z; Sun HD; Chen SJ
Cell Death Differ; 2007 Feb; 14(2):306-17. PubMed ID: 16778832
[TBL] [Abstract][Full Text] [Related]
13. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Kagoya Y; Yoshimi A; Kataoka K; Nakagawa M; Kumano K; Arai S; Kobayashi H; Saito T; Iwakura Y; Kurokawa M
J Clin Invest; 2014 Feb; 124(2):528-42. PubMed ID: 24382349
[TBL] [Abstract][Full Text] [Related]
14. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
Huang G; Zhao X; Wang L; Elf S; Xu H; Zhao X; Sashida G; Zhang Y; Liu Y; Lee J; Menendez S; Yang Y; Yan X; Zhang P; Tenen DG; Osato M; Hsieh JJ; Nimer SD
Blood; 2011 Dec; 118(25):6544-52. PubMed ID: 22012064
[TBL] [Abstract][Full Text] [Related]
15. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
Yu P; Petrus MN; Ju W; Zhang M; Conlon KC; Nakagawa M; Maeda M; Bamford RN; Waldmann TA
Leukemia; 2015 Mar; 29(3):556-66. PubMed ID: 25118879
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
17. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
Su YL; Wang X; Mann M; Adamus TP; Wang D; Moreira DF; Zhang Z; Ouyang C; He X; Zhang B; Swiderski PM; Forman SJ; Baltimore D; Li L; Marcucci G; Boldin MP; Kortylewski M
Blood; 2020 Jan; 135(3):167-180. PubMed ID: 31805184
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
Liu S; Liu Z; Xie Z; Pang J; Yu J; Lehmann E; Huynh L; Vukosavljevic T; Takeki M; Klisovic RB; Baiocchi RA; Blum W; Porcu P; Garzon R; Byrd JC; Perrotti D; Caligiuri MA; Chan KK; Wu LC; Marcucci G
Blood; 2008 Feb; 111(4):2364-73. PubMed ID: 18083845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
